Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Ayala Pharmaceuticals Inc
(OP:
ADXS
)
0.0200
-0.0005 (-2.44%)
Streaming Delayed Price
Updated: 12:55 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
225
Open
0.0200
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.0205
Today's Range
0.0200 - 0.0200
52wk Range
0.0012 - 1.490
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations
May 09, 2024
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
March 26, 2024
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Performance
YTD
-96.83%
-96.83%
1 Month
+1566.67%
+1566.67%
3 Month
-93.74%
-93.74%
6 Month
-97.78%
-97.78%
1 Year
-98.00%
-98.00%
More News
Read More
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
February 20, 2024
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
February 06, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
February 06, 2024
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
November 06, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
October 23, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
October 19, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 10, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023
August 01, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
July 27, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors
July 05, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
June 05, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 30, 2023
May 30, 2023
Via
Benzinga
Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 25, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update
May 23, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Inc. (OTC:ADXS) Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors
March 08, 2023
Via
News Direct
Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee
March 03, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022
February 10, 2023
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Ayala Pharmaceuticals and Advaxis Agree To Combine, Expect Uplisting On NASDAQ
October 19, 2022
Via
Benzinga
Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement
October 19, 2022
From
Ayala Pharmaceuticals
Via
GlobeNewswire
ADXS Investor Alert – Monteverde & Associates PC and Kahn Swick & Foti, LLC Obtain Material Disclosures Regarding the Upcoming Shareholder Vote for Advaxis, Inc. - ADXS
March 28, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
December 22, 2021
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
December 10, 2021
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.